Drug Trial Radar · NCT01450761
Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone
Last checked: Nov 20, 2026Latest source record: Jul 8, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,351
Actual
Start
Dec 13, 2011
Primary completion
Mar 19, 2015
Study completion May 17, 2017
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Oct 12, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to determine whether the addition of Ipilimumab to Etoposide and Platinum therapy will extend the lives of patients with Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) more than Etoposide and Platinum therapy alone.
Conditions
- Small Cell Lung Carcinoma
Interventions
IpilimumabBiological
Placebo matching IpilimumabBiological
EtoposideDrug
CisplatinDrug
CarboplatinDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS) in Participants Who Received at Least One Dose of Blinded Study TherapyTime frame: Randomization until date of death, up to March 2015, approximately 38 months
Locations
225 sites in 34 countries. Site status is shown where the registry gives one.
Genesis Cancer Center
Hot Springs, Arkansas
Sutter Medical Center
Auburn, California
UCSD Moores Cancer Center
La Jolla, California
University Of Colorado Cancer Center
Aurora, Colorado
Florida Cancer Specialists S.
Fort Myers, Florida
Cancer Specialists, LLC
Jacksonville, Florida
Lake City Cancer Care
Lake City, Florida
Florida Cancer Specialists
St. Petersburg, Florida
Medical Oncology, LLC
Augusta, Georgia
Quincy Medical Group
Quincy, Illinois
Presence Medical Group Hematology Oncology
Skokie, Illinois
SIU School Of Medicine
Springfield, Illinois
St. Francis Medical Group Oncology And Hematology Specialist
Indianapolis, Indiana
Cancer Center Of Kansas
Wichita, Kansas
Ashland Bellefonte Cancer Center
Ashland, Kentucky
University Of Kentucky
Lexington, Kentucky
Montgomery Cancer Center
Mount Sterling, Kentucky
St Joseph Mercy Hospital
Ypsilanti, Michigan
St. Luke'S Cancer Institute
Kansas City, Missouri
Southeast Nebraska Hematology & Oncology Consultants, P.C.
Lincoln, Nebraska
Regional Cancer Care Associates, LLC/Cherry Hill Division
Cherry Hill, New Jersey
Memorial Sloan Kettering Nassau
New York, New York
Gabrail Cancer Center
Canton, Ohio
Oncology Hematology Care, Incorporated
Cincinnati, Ohio
University Hospitals
Cleveland, Ohio
Signal Point Clinical Research Center, Llc
Middletown, Ohio
Oklahoma Cancer Specialists and Research Institute, LLC
Tulsa, Oklahoma
Providence Portland Medical Center
Portland, Oregon
Kaiser Permanente
Portland, Oregon
Chattanooga Oncology Hematology Associates
Chattanooga, Tennessee
Associated in Oncology and Hematology
Chattanooga, Tennessee
The Jones Clinic, PC
Germantown, Tennessee
Tennessee Cancer Specialists
Knoxville, Tennessee
Thompson Cancer Survival Center
Knoxville, Tennessee
Tennessee Oncology, PLLC
Nashville, Tennessee
Henry-Joyce Cancer Center
Nashville, Tennessee
University Of Texas, M. D. Anderson Cancer Center
Houston, Texas
Joe Arrington Cancer Research And Treatment Center
Lubbock, Texas
Huntsman Cancer Hospital
Salt Lake City, Utah
Virginia Cancer Institute
Richmond, Virginia
Showing 40 of 225 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.